FILED - A test for the coronavirus from the Swiss company Roche sits on a table in this illustrative shot from March 18, 2021. Photo: Frank Molter/dpa
FILED - A test for the coronavirus from the Swiss company Roche sits on a table in this illustrative shot from March 18, 2021. Photo: Frank Molter/dpa

(dpa) – Swiss pharmaceutical giant Roche on Monday presented new data on its phase three trial of an antibody cocktail that is meant to reduce the risk of a symptomatic case of Covid-19.

The Basel-headquartered company said that its latest data set showed that the subcutaneous administration of a cocktail of casirivimab and imdevimab reduced the risk of a symptomatic case by 81 per cent.

“Among individuals who still experienced symptomatic infections, those who received casirivimab and imdevimab were able to clear the virus faster and had much shorter symptom duration,” the company said in a statement.

It added that a in group of recently infected asymptomatic patients, the cocktail reduced the risk of progressing to symptomatic Covid-19 by 31 per cent.

The data would be shared with regulatory authorities in Europe and the United States, the company said.

Disclaimer: News Ghana is not responsible for the reportage or opinions of contributors published on the website.

Send your news stories to [email protected] and via WhatsApp on +1-508-812-0505 

Previous articleItalian investigators conduct raids in major anti-Mafia operation
Next articleHuge crowds at India’s Kumbh festival as coronavirus pandemic surges

LEAVE A REPLY

Please enter your comment!
Please enter your name here